Pharmaceutical Liability
FDA Includes Black Box Warning on Gout Medicine Uloric
As of February 2019, the U.S. Food and Drug Administration has stated that there is a higher risk of death associated with gout medicine Uloric…
Read MoreXeljanz
Xeljanz is a Janus kinase (JAK) inhibitor that is commonly prescribed to treat patients with rheumatoid arthritis, psoriatic arthritis and ulcerative colitis by helping to…
Read MoreUpdates on Risks Surrounding Proton Pump Inhibitors (PPIs)
Proton pump inhibitors (PPIs) decrease the production of stomach acid that is responsible for the development of ulcers in the stomach, duodenum and esophagus. However,…
Read MoreZostavax 2019 Litigation Updates
Zostavax, a vaccine administered to protect against herpes zoster, otherwise known as shingles, is now being contested in approximately 550 cases in multidistrict litigation (MDL).…
Read MoreUpdates on Safety Doubts Surrounding Nuplazid
In June of 2016, antipsychotic pharmaceutical drug Nuplazid was approved as a new method of treating psychosis in Parkinson’s patients. Since it’s release over two…
Read MoreDrug Watch — Lemtrada
The Food and Drug Administration (FDA) has recently added a warning to the prescribing information of Lemtrada, a pharmaceutical drug used to treat serious multiple…
Read MoreCarcinogenic Impurities in Valsartan Lead to Legal Action
On July 13th, 2018, the Food and Drug Administration (FDA) announced that several pharmaceutical companies were voluntarily recalling certain batches of valsartan-containing blood pressure medication…
Read MoreThe Opioid Crisis by The Numbers
Opioid Liability for Injury and Death
The opioid industry is facing unprecedented backlash from private citizens and government officials as more individuals fall victim to addiction, injury and even death related…
Read MoreJury Awards $27.8 Million in Damages to Patient Injured by Xarelto®
On December 5, 2017, a Philadelphia jury ordered Bayer AG and Johnson & Johnson to pay over $27 million in damages to a patient injured…
Read More